Stacey M Bagby Selected Research

RX-5902

11/2020	RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
11/2019	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stacey M Bagby Research Topics

Disease

24	Neoplasms (Cancer) 01/2022 - 01/2014
7	Melanoma (Melanoma, Malignant) 10/2021 - 01/2017
7	Colorectal Neoplasms (Colorectal Cancer) 10/2018 - 01/2014
4	Triple Negative Breast Neoplasms 11/2020 - 11/2019
2	Adenocarcinoma 01/2021 - 01/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2020 - 01/2018
2	Aneuploidy (Aneuploid) 11/2019 - 10/2018
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Adrenocortical Carcinoma 01/2020
1	Polyploidy 01/2018
1	Neoplasm Metastasis (Metastasis) 01/2018

Drug/Important Bio-Agent (IBA)

5	Phosphotransferases (Kinase)IBA 10/2018 - 01/2014
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2021 - 01/2014
4	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2020
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2017
2	Histones (Histone)IBA 01/2022 - 10/2019
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2021
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2018
2	adavosertibIBA 01/2021 - 03/2020
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 12/2017
2	Capecitabine (Xeloda)FDA Link 01/2021 - 03/2020
2	RX-5902IBA 11/2020 - 11/2019
2	CateninsIBA 11/2020 - 11/2019
2	Pharmaceutical PreparationsIBA 10/2020 - 01/2017
2	Aurora Kinase AIBA 01/2020 - 01/2015
2	MLN 8237IBA 01/2020 - 08/2016
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2018
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2022
1	Histone Deacetylase InhibitorsIBA 01/2022
1	palbociclibIBA 10/2021
1	trametinibIBA 10/2021
1	CytokinesIBA 01/2021
1	Gemcitabine FDA Link 10/2020
1	Hormones (Hormone)IBA 03/2020
1	sapanisertibIBA 01/2020
1	Granzymes (Granzyme)IBA 01/2020
1	Genetic Markers (Genetic Marker)IBA 01/2020
1	pembrolizumabIBA 01/2020
1	S63845IBA 01/2020
1	navitoclaxIBA 01/2020
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2020
1	UNC2025IBA 01/2019
1	c-Mer Tyrosine KinaseIBA 01/2019
1	VemurafenibIBA 01/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019
1	ENMD 2076IBA 10/2018
1	cabozantinibIBA 10/2018
1	Chloroquine (Aralen)FDA LinkGeneric 10/2018
1	tyrosine receptor (receptor, tyrosine)IBA 10/2018
1	regorafenibIBA 10/2018
1	SBI-0206965IBA 10/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	Enterotoxin ReceptorsIBA 01/2018
1	4- ((9- cyclopentyl- 7,7- difluoro- 5- methyl- 6- oxo- 6,7,8,9- tetrahydro- 5H- pyrimido(4,5- b)(1,4)diazepin- 2- yl)amino)- 2- fluoro- 5- methoxy- N- (1- methylpiperidin- 4- yl)benzamideIBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	entrectinibIBA 01/2018
1	AldosteroneIBA 01/2018
1	Adenosine Triphosphate (ATP)IBA 01/2018
1	indusatumabIBA 01/2018
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2017
1	pevonedistatIBA 01/2017
1	TAK 733IBA 10/2015
1	Drug CombinationsIBA 01/2015
1	mirdametinibIBA 01/2014

Therapy/Procedure

10	Therapeutics 10/2021 - 01/2015
3	Immunotherapy 01/2021 - 01/2020
1	Salvage Therapy 10/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Molecular Targeted Therapy 01/2020